Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-42

Interesting - moderately positive for me.

I like the idea of 'definitive unblinded data' after 6 months.

Three arms....Placebo, 25mg and 50 Mg.

With a bit of luck, we won't need a P3...if we can apply for early access.

Can't help but feel Sarepta / or another party is waiting in the wings for partnership, but looking for more expansive data set with placebo control.

The Company believes that if successful, positive data from a controlled trial of ATL1102 in DMD patients could add substantial value to the program and, based on previous external feedback, garner serious partnering interest at an earlier point in the development program than previously anticipated.
.